stoxline Quote Chart Rank Option Currency Glossary
Agile Therapeutics, Inc. (AGRX)
1.43  -0.01 (-0.69%)    07-23 14:53
Open: 1.43
High: 1.44
Volume: 4,325
Pre. Close: 1.44
Low: 1.43
Market Cap: 10(M)
Technical analysis
2024-07-23 4:50:16 PM
Short term     
Mid term     
Targets 6-month :  1.69 1-year :  1.97
Resists First :  1.45 Second :  1.69
Pivot price 1.42
Supports First :  0.74 Second :  0.31
MAs MA(5) :  1.43 MA(20) :  1.37
MA(100) :  0.62 MA(250) :  1.4
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  70.4 D(3) :  80.9
RSI RSI(14): 83
52-week High :  3 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AGRX ] has closed below upper band by 46.9%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.44 - 1.45 1.45 - 1.46
Low: 1.41 - 1.42 1.42 - 1.43
Close: 1.42 - 1.43 1.43 - 1.44
Company Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Headline News

Wed, 17 Jul 2024
Agile Therapeutics (NASDAQ:AGRX) Share Price Passes Above 50 Day Moving Average of $0.68 - Defense World

Wed, 17 Jul 2024 Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX) - Defense World

Mon, 15 Jul 2024
Kuehn Law Encourages AGRX, SPR, ENV, and UMBF Investors to Contact Law Firm - Morningstar

Wed, 03 Jul 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX - PR Newswire

Fri, 28 Jun 2024
AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX - Business Wire

Wed, 26 Jun 2024
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 7 (M)
Shares Float 6 (M)
Held by Insiders 9.2 (%)
Held by Institutions 9.9 (%)
Shares Short 222 (K)
Shares Short P.Month 190 (K)
Stock Financials
EPS -0.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.51
Profit Margin -36.3 %
Operating Margin -48.3 %
Return on Assets (ttm) -75.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 49.9 %
Gross Profit (p.s.) 0
Sales Per Share 3.13
EBITDA (p.s.) -2.27
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -2.75
PEG Ratio 0
Price to Book value -0.95
Price to Sales 0.45
Price to Cash Flow -0.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android